

Isocitrate Dehydrogenase (IDH) inhibitors- Pipeline Insight, 2022

<https://marketpublishers.com/r/IB6972CD10FEN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: IB6972CD10FEN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Isocitrate Dehydrogenase (IDH) inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Isocitrate Dehydrogenase (IDH) inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Isocitrate Dehydrogenase (IDH) inhibitors Understanding

Isocitrate Dehydrogenase (IDH) inhibitors: Overview

Isocitrate dehydrogenase (IDH) is a key enzyme involved in the conversion of isocitrate to α -ketoglutarate (α -KG) in the tricarboxylic acid (TCA) cycle. IDH mutation produces a neomorphic enzyme, which can lead to the abnormal accumulation of R-2-HG and promotes leukemogenesis.

IDH mutation occurs in 20% of acute myeloid leukemia (AML) patients, mainly including IDH1 R132, IDH2 R140, and IDH2 R172. Different mutant isoforms have different prognostic values.

Mutations in the enzyme isocitrate dehydrogenase 1 (IDH1) lead to metabolic alterations and a sustained formation of 2-hydroxyglutarate (2-HG). 2-HG is an oncometabolite as it inhibits the activity of α -ketoglutarate-dependent dioxygenases such as ten-eleven translocation (TET) enzymes.

Isocitrate Dehydrogenase (IDH) inhibitors Emerging Drugs Chapters

This segment of the Isocitrate Dehydrogenase (IDH) inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Isocitrate Dehydrogenase (IDH) inhibitors Emerging Drugs

Vorasidenib: Agios Pharmaceuticals

Vorasidenib, an investigational, oral, selective, brain-penetrant inhibitor of mutant IDH1 and IDH2 enzymes, is currently being evaluated in the registration-enabling Phase 3 INDIGO study as a potential treatment for patients with residual or recurrent Grade 2 non-enhancing glioma.

Further product details are provided in the report.....

Isocitrate Dehydrogenase (IDH) inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Isocitrate Dehydrogenase (IDH) inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Isocitrate Dehydrogenase (IDH) inhibitors

There are approx. 10+ key companies which are developing the Isocitrate Dehydrogenase (IDH) inhibitors. The companies which have their Isocitrate Dehydrogenase (IDH) inhibitors drug candidates in the most advanced stage, i.e. phase

III include, Agios Pharmaceuticals.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Isocitrate Dehydrogenase (IDH) inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Isocitrate Dehydrogenase (IDH) inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Isocitrate Dehydrogenase (IDH) inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Isocitrate Dehydrogenase (IDH) inhibitors drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Isocitrate Dehydrogenase (IDH) inhibitors R&D. The therapies under development are focused on novel approaches for Isocitrate Dehydrogenase (IDH) inhibitors.

May 2020: May 2020, Agios Pharmaceuticals reported updated data from the ongoing Phase 1 study evaluating single agent vorasidenib in isocitrate dehydrogenase (IDH)-mutant advanced solid tumors, including glioma. Data from the non-enhancing glioma population were featured in an oral presentation at the 2020 American Society of Clinical Oncology (ASCO) annual meeting, which is being held virtually.

Isocitrate Dehydrogenase (IDH) inhibitors Report Insights

Isocitrate Dehydrogenase (IDH) inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Isocitrate Dehydrogenase (IDH) inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Isocitrate Dehydrogenase (IDH) inhibitors drugs?

How many Isocitrate Dehydrogenase (IDH) inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Isocitrate Dehydrogenase (IDH) inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Isocitrate Dehydrogenase (IDH) inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Isocitrate Dehydrogenase (IDH) inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Bayer

Agios Pharma

Daiichi Sankyo

Ohm Oncology

Key Products

BAY 1436032

Vorasidenib

DS 1001

OMT 004

Contents

Introduction

Executive Summary

Isocitrate Dehydrogenase (IDH) inhibitors: Overview

- Structure
- Mechanism of Action

Pipeline Therapeutics

- Comparative Analysis

Therapeutic Assessment

- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type

Isocitrate Dehydrogenase (IDH) inhibitors – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

- Isocitrate Dehydrogenase (IDH) inhibitors companies' collaborations, Licensing, Acquisition -Deal Value Trends

Isocitrate Dehydrogenase (IDH) inhibitors Collaboration Deals

- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

- Comparative Analysis

Vorasidenib: Agios Pharmaceuticals

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

- Comparative Analysis

Drug Name: Company Name

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

- Comparative Analysis

Drug Name: Company Name

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

- Comparative Analysis

Isocitrate Dehydrogenase (IDH) inhibitors Key Companies

Isocitrate Dehydrogenase (IDH) inhibitors Key Products

Isocitrate Dehydrogenase (IDH) inhibitors- Unmet Needs

Isocitrate Dehydrogenase (IDH) inhibitors- Market Drivers and Barriers

Isocitrate Dehydrogenase (IDH) inhibitors- Future Perspectives and Conclusion

Isocitrate Dehydrogenase (IDH) inhibitors Analyst Views

Isocitrate Dehydrogenase (IDH) inhibitors Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Isocitrate Dehydrogenase (IDH) inhibitors

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Isocitrate Dehydrogenase (IDH) inhibitors

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Isocitrate Dehydrogenase (IDH) inhibitors- Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/IB6972CD10FEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IB6972CD10FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970